Company Overview
The HHT Foundation is dedicated to making a positive impact in the lives of individuals affected by Hereditary Hemorrhagic Telangiectasia (HHT). This disease, also known as Osler-Weber-Rendu syndrome, affects over 1.4 million people worldwide, with many unaware of its potentially life-threatening nature. We are the only patient advocacy organization solely focused on HHT, and our mission is to improve the lives of HHT patients through research, access to care, and standardization of treatments.
At the core of our work is a commitment to funding research on promising therapies for HHT. We understand that finding a cure for this disease is crucial for improving the lives of those affected by it. That's why we invest in "seed money" for research, providing the necessary resources for scientists and doctors to explore new treatments and potential cures. By supporting innovative research, we are paving the way for a better future for HHT patients.
